Anti-Blood Cancer Compound Library | 抗血液肿瘤化合物库 | MedChemExpress (MCE)

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 2,706 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.更多产品详情查看：www.medchemexpress.cn/screening/anti-blood-cancer-compound-library.html

Anti-Blood Cancer Compound Library | 抗血液肿瘤化合物库 | MedChemExpress (MCE)信息由MedChemExpress (MCE)为您提供，如您想了解更多关于Anti-Blood Cancer Compound Library | 抗血液肿瘤化合物库 | MedChemExpress (MCE)报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途